Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma (CORE-MM)
NCT07637578Phase 2Recruiting
- Sponsor
- SCRI Development Innovations
- Start
- Sep 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Phase 2, open-label trial of elranatamab in multiple myeloma (MM) (2 cohorts), sponsored by SCRI Development Innovations. Primary endpoint: Incidence of Cytokine Release Syndrome (CRS) in Cycle 1 at 28 days. Started Sep 2026; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07637578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07637578.